Two newly identified sites in the N -terminal regulatory domain of Aurora-A are essential for auto-inhibition

Meirong Bai,Jun Ni,Sunqin Shen,Jiaxue Wu,Qiang Huang,Yichen Le,Long Yu

DOI: https://doi.org/10.1007/s10529-014-1516-3

2014-01-01

Biotechnology Letters

Abstract:Aurora-A, a centrosome-localized serine/threonine kinase, is over-expressed in multiple human cancers. We previously reported Zhang et al. (Biochem Biophys Res Commun 2007 , 357:347–352) intramolecular inhibitory regulation of Aurora-A between its N -terminal (Nt) regulatory domain (amino acids 1–128, Nt) and C -terminal catalytic domain (aa 129–403, Cd). Here, we identified two essential sites located on the Nt of Aurora-A (Lys 99 and Lys 119) and demonstrate that mutation of either residue to Gly could cause the Nt and C -terminal lobes of the catalytic domain in Aurora-A to form a closed conformation, resulting in a loss of kinase activity. This inactive conformation was reversed by adding C26 peptide (274–299) or Ajuba, which is a required activator of Aurora-A. Over-expression of either mutant induced G2/M arrest. These results provide a basis for future anti-cancer studies targeting Aurora-A.